Immune-related lichenoid mucocutaneous erosions during anti-PD-1 immunotherapy in metastatic renal cell carcinoma - A case report
Nivolumab belongs to the standard treatment options in metastatic renal cell carcinoma. Despite promising responses, a new spectrum of “immune-related” adverse effects has to be managed in daily clinical practice. A 74-year-old patient was treated with nivolumab in fourth-line. After 18 cycles, trea...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-03-01
|
| Series: | Urology Case Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214442018303528 |
| _version_ | 1811278035197886464 |
|---|---|
| author | Andrea Katharina Lindner Gert Schachtner Gennadi Tulchiner Nina Staudacher Fabian Steinkohl Van Anh Nguyen Wolfgang Horninger Renate Pichler |
| author_facet | Andrea Katharina Lindner Gert Schachtner Gennadi Tulchiner Nina Staudacher Fabian Steinkohl Van Anh Nguyen Wolfgang Horninger Renate Pichler |
| author_sort | Andrea Katharina Lindner |
| collection | DOAJ |
| description | Nivolumab belongs to the standard treatment options in metastatic renal cell carcinoma. Despite promising responses, a new spectrum of “immune-related” adverse effects has to be managed in daily clinical practice. A 74-year-old patient was treated with nivolumab in fourth-line. After 18 cycles, treatment was stopped due to severe adverse mucocutaneous reactions confirming a lichen ruber pemphigoides. CT scans during treatment discontinuation show stable disease since more than 14 months. Immunotherapy can cause mucocutaneous immune-mediated adverse reactions. The time of onset to cutaneous adverse effects is variable. Early recognition and treatment are essential in mitigating the severity of those adverse events. Keywords: Renal cell cancer, Nivolumab, Lichen ruber, Side effects, Cutaneous adverse event |
| first_indexed | 2024-04-13T00:27:28Z |
| format | Article |
| id | doaj.art-139489dff70349a8a74f2e0f84b27c98 |
| institution | Directory Open Access Journal |
| issn | 2214-4420 |
| language | English |
| last_indexed | 2024-04-13T00:27:28Z |
| publishDate | 2019-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Urology Case Reports |
| spelling | doaj.art-139489dff70349a8a74f2e0f84b27c982022-12-22T03:10:33ZengElsevierUrology Case Reports2214-44202019-03-012312Immune-related lichenoid mucocutaneous erosions during anti-PD-1 immunotherapy in metastatic renal cell carcinoma - A case reportAndrea Katharina Lindner0Gert Schachtner1Gennadi Tulchiner2Nina Staudacher3Fabian Steinkohl4Van Anh Nguyen5Wolfgang Horninger6Renate Pichler7Medical University of Innsbruck, Department of Urology, Anichstrasse 35, Innsbruck, AustriaMedical University of Innsbruck, Department of Urology, Anichstrasse 35, Innsbruck, AustriaMedical University of Innsbruck, Department of Urology, Anichstrasse 35, Innsbruck, AustriaMedical University of Innsbruck, Department of Urology, Anichstrasse 35, Innsbruck, AustriaDepartment of Radiology, Anichstrasse 35, Innsbruck, AustriaDepartment of Dermatology, Venereology and Allergy, Anichstrasse 35, Innsbruck, AustriaMedical University of Innsbruck, Department of Urology, Anichstrasse 35, Innsbruck, AustriaMedical University of Innsbruck, Department of Urology, Anichstrasse 35, Innsbruck, Austria; Corresponding author. Medical University Innsbruck Department of Urology, Anichstrasse 35, Innsbruck, Austria.Nivolumab belongs to the standard treatment options in metastatic renal cell carcinoma. Despite promising responses, a new spectrum of “immune-related” adverse effects has to be managed in daily clinical practice. A 74-year-old patient was treated with nivolumab in fourth-line. After 18 cycles, treatment was stopped due to severe adverse mucocutaneous reactions confirming a lichen ruber pemphigoides. CT scans during treatment discontinuation show stable disease since more than 14 months. Immunotherapy can cause mucocutaneous immune-mediated adverse reactions. The time of onset to cutaneous adverse effects is variable. Early recognition and treatment are essential in mitigating the severity of those adverse events. Keywords: Renal cell cancer, Nivolumab, Lichen ruber, Side effects, Cutaneous adverse eventhttp://www.sciencedirect.com/science/article/pii/S2214442018303528 |
| spellingShingle | Andrea Katharina Lindner Gert Schachtner Gennadi Tulchiner Nina Staudacher Fabian Steinkohl Van Anh Nguyen Wolfgang Horninger Renate Pichler Immune-related lichenoid mucocutaneous erosions during anti-PD-1 immunotherapy in metastatic renal cell carcinoma - A case report Urology Case Reports |
| title | Immune-related lichenoid mucocutaneous erosions during anti-PD-1 immunotherapy in metastatic renal cell carcinoma - A case report |
| title_full | Immune-related lichenoid mucocutaneous erosions during anti-PD-1 immunotherapy in metastatic renal cell carcinoma - A case report |
| title_fullStr | Immune-related lichenoid mucocutaneous erosions during anti-PD-1 immunotherapy in metastatic renal cell carcinoma - A case report |
| title_full_unstemmed | Immune-related lichenoid mucocutaneous erosions during anti-PD-1 immunotherapy in metastatic renal cell carcinoma - A case report |
| title_short | Immune-related lichenoid mucocutaneous erosions during anti-PD-1 immunotherapy in metastatic renal cell carcinoma - A case report |
| title_sort | immune related lichenoid mucocutaneous erosions during anti pd 1 immunotherapy in metastatic renal cell carcinoma a case report |
| url | http://www.sciencedirect.com/science/article/pii/S2214442018303528 |
| work_keys_str_mv | AT andreakatharinalindner immunerelatedlichenoidmucocutaneouserosionsduringantipd1immunotherapyinmetastaticrenalcellcarcinomaacasereport AT gertschachtner immunerelatedlichenoidmucocutaneouserosionsduringantipd1immunotherapyinmetastaticrenalcellcarcinomaacasereport AT gennaditulchiner immunerelatedlichenoidmucocutaneouserosionsduringantipd1immunotherapyinmetastaticrenalcellcarcinomaacasereport AT ninastaudacher immunerelatedlichenoidmucocutaneouserosionsduringantipd1immunotherapyinmetastaticrenalcellcarcinomaacasereport AT fabiansteinkohl immunerelatedlichenoidmucocutaneouserosionsduringantipd1immunotherapyinmetastaticrenalcellcarcinomaacasereport AT vananhnguyen immunerelatedlichenoidmucocutaneouserosionsduringantipd1immunotherapyinmetastaticrenalcellcarcinomaacasereport AT wolfganghorninger immunerelatedlichenoidmucocutaneouserosionsduringantipd1immunotherapyinmetastaticrenalcellcarcinomaacasereport AT renatepichler immunerelatedlichenoidmucocutaneouserosionsduringantipd1immunotherapyinmetastaticrenalcellcarcinomaacasereport |